ALSUntangled 59: Tamoxifen: The Alsuntangled Group

Richard Bedlack; Sky Kihuwa-mani; Paul E. Barkhaus; Michael Bereman; James B. Caress; Jesse Crayle; Gary L. Pattee; Terry Heiman Patterson; Paul Wicks; Neta Zach; Gregory T. Carter; Kristiana Salmon

doi:10.1080/21678421.2021.1876731

ALSUntangled 59: Tamoxifen: The Alsuntangled Group

Richard Bedlack, Sky Kihuwa-mani, Paul E. Barkhaus, Michael Bereman, James B. Caress, Jesse Crayle, Gary L. Pattee, Terry Heiman Patterson, Paul Wicks, Neta Zach, Gregory T. Carter, Kristiana Salmon

Research output: Contribution to journal › Article › peer-review

Abstract

Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has plausible mechanisms, a positive preclinical study, a case report and 2 small trials suggesting benefits. We show that it appears reasonably safe, though there is a small risk of developing cancer with long term use. While we cannot yet endorse this as an ALS treatment, there is enough evidence to warrant another larger ALS trial.

Original language	English
Pages (from-to)	595-598
Number of pages	4
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	22
Issue number	7-8
DOIs	https://doi.org/10.1080/21678421.2021.1876731
State	Published - 2021

Keywords

ALSUntangled
Tamoxifen
clinical trials
ethics
off-label treatment
therapy
trials

Access to Document

10.1080/21678421.2021.1876731

Cite this

@article{fe21cea11c0245d4b9b010466087ba50,

title = "ALSUntangled 59: Tamoxifen: The Alsuntangled Group",

abstract = "Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has plausible mechanisms, a positive preclinical study, a case report and 2 small trials suggesting benefits. We show that it appears reasonably safe, though there is a small risk of developing cancer with long term use. While we cannot yet endorse this as an ALS treatment, there is enough evidence to warrant another larger ALS trial.",

keywords = "ALSUntangled, Tamoxifen, clinical trials, ethics, off-label treatment, therapy, trials",

author = "Richard Bedlack and Sky Kihuwa-mani and Barkhaus, {Paul E.} and Michael Bereman and Caress, {James B.} and Jesse Crayle and Pattee, {Gary L.} and {Heiman Patterson}, Terry and Paul Wicks and Neta Zach and Carter, {Gregory T.} and Kristiana Salmon",

note = "Publisher Copyright: {\textcopyright} 2021 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2021",

doi = "10.1080/21678421.2021.1876731",

language = "English",

volume = "22",

pages = "595--598",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "7-8",

}

TY - JOUR

T1 - ALSUntangled 59

T2 - Tamoxifen: The Alsuntangled Group

AU - Bedlack, Richard

AU - Kihuwa-mani, Sky

AU - Barkhaus, Paul E.

AU - Bereman, Michael

AU - Caress, James B.

AU - Crayle, Jesse

AU - Pattee, Gary L.

AU - Heiman Patterson, Terry

AU - Wicks, Paul

AU - Zach, Neta

AU - Carter, Gregory T.

AU - Salmon, Kristiana

PY - 2021

Y1 - 2021

N2 - Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has plausible mechanisms, a positive preclinical study, a case report and 2 small trials suggesting benefits. We show that it appears reasonably safe, though there is a small risk of developing cancer with long term use. While we cannot yet endorse this as an ALS treatment, there is enough evidence to warrant another larger ALS trial.

AB - Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has plausible mechanisms, a positive preclinical study, a case report and 2 small trials suggesting benefits. We show that it appears reasonably safe, though there is a small risk of developing cancer with long term use. While we cannot yet endorse this as an ALS treatment, there is enough evidence to warrant another larger ALS trial.

KW - ALSUntangled

KW - Tamoxifen

KW - clinical trials

KW - ethics

KW - off-label treatment

KW - therapy

KW - trials

UR - http://www.scopus.com/inward/record.url?scp=85099848245&partnerID=8YFLogxK

U2 - 10.1080/21678421.2021.1876731

DO - 10.1080/21678421.2021.1876731

M3 - Article

C2 - 33474997

AN - SCOPUS:85099848245

SN - 2167-8421

VL - 22

SP - 595

EP - 598

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 7-8

ER -

ALSUntangled 59: Tamoxifen: The Alsuntangled Group

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this